10X GENOMICS INC-CLASS A (TXG)
US88025U1097 - Common Stock
TXG gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. TXG has a great financial health rating, but its profitability evaluates not so good. TXG is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TXG has reported negative net income.
TXG had a positive operating cash flow in the past year.
In the past 5 years TXG always reported negative net income.
TXG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TXG has a worse Return On Assets (-19.47%) than 60.00% of its industry peers.
TXG has a Return On Equity (-25.26%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.47% | ||
| ROE | -25.26% | ||
| ROIC | N/A |
ROA(3y)-16.09%
ROA(5y)-22.37%
ROE(3y)-20.72%
ROE(5y)-28.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TXG's Gross Margin of 66.63% is amongst the best of the industry. TXG outperforms 96.36% of its industry peers.
In the last couple of years the Gross Margin of TXG has declined.
The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.32%
GM growth 5Y-3.84%
2. Health
2.1 Basic Checks
TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TXG has been increased compared to 1 year ago.
Compared to 5 years ago, TXG has more shares outstanding
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
TXG has an Altman-Z score of 3.93. This indicates that TXG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.93, TXG is in the better half of the industry, outperforming 65.45% of the companies in the same industry.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.93 |
ROIC/WACCN/A
WACC10.33%
2.3 Liquidity
TXG has a Current Ratio of 4.90. This indicates that TXG is financially healthy and has no problem in meeting its short term obligations.
TXG's Current ratio of 4.90 is fine compared to the rest of the industry. TXG outperforms 74.55% of its industry peers.
A Quick Ratio of 4.12 indicates that TXG has no problem at all paying its short term obligations.
TXG's Quick ratio of 4.12 is fine compared to the rest of the industry. TXG outperforms 69.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 19.90% over the past year.
Looking at the last year, TXG shows a small growth in Revenue. The Revenue has grown by 6.57% in the last year.
Measured over the past years, TXG shows a very strong growth in Revenue. The Revenue has been growing by 33.43% on average per year.
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.03%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y33.43%
Sales Q2Q%-1.3%
3.2 Future
The Earnings Per Share is expected to grow by 24.66% on average over the next years. This is a very strong growth
TXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.60% yearly.
EPS Next Y34.45%
EPS Next 2Y19.75%
EPS Next 3Y17.64%
EPS Next 5Y24.66%
Revenue Next Year-2.87%
Revenue Next 2Y1.53%
Revenue Next 3Y4.09%
Revenue Next 5Y12.6%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
TXG's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 76.85 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TXG's earnings are expected to grow with 17.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.75%
EPS Next 3Y17.64%
5. Dividend
5.1 Amount
TXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10X GENOMICS INC-CLASS A
NASDAQ:TXG (11/11/2024, 8:06:48 PM)
Premarket: 15.91 +0.01 (+0.06%)15.9
+0.26 (+1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.92B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.47% | ||
| ROE | -25.26% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.9 | ||
| Quick Ratio | 4.12 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y34.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y